Histological Study and LYVE-1 Immunolocalization of Mouse Mesenteric Lymph Nodes with “In Vivo Cryotechnique”

The “in vivo cryotechnique” (IVCT) is a powerful tool to directly freeze living animal organs in order to maintain biological components in frozen tissues, reflecting their native states. In this study, mesenteric lymph nodes of living mice were directly frozen with IVCT, and we did morphological studies and immunohistochemical analyses on a hyaluronic acid receptor, LYVE-1. In lymph nodes, widely open lymphatic sinuses were observed, and many lymphocytes adhered to inner endothelial cells along subcapsular sinuses. The LYVE-1 was clearly immunolocalized at inner endothelial cells of subcapsular sinuses, as well as those of medullary sinuses. Conventional pre-embedding electron microscopy also showed LYVE-1 immunolocalization along both the apical and basal sides of cell membranes of inner endothelial cells. By triple-immunostaining for LYVE-1, smooth muscle actin, and type IV collagen, the LYVE-1 was immunolocalized only in the inner endothelial cells, but not in outer ones which were surrounded by collagen matrix and smooth muscle cells. Thus, the functional morphology of lymph nodes in vivo was demonstrated and LYVE-1 immunolocalization in inner endothelial cells of subcapsular sinuses suggests hyaluronic acid incorporation into lymph node parenchyma

Satellite-based estimate of the variability of warm cloud properties associated with aerosol and meteorological conditions

Aerosol-cloud interaction (ACI) is examined using 10 years of data from the MODIS/Terra (morning orbit) and MODIS/Aqua (afternoon orbit) satellites. Aerosol optical depth (AOD) and cloud properties retrieved from both sensors are used to explore in a statistical sense the morning-to-afternoon variation of cloud properties in conditions with low and high AOD, over both land and ocean. The results show that the interaction between aerosol particles and clouds is more complex and of greater uncertainty over land than over ocean. The variation in d(Cloud_X), defined as the mean change in cloud property Cloud_X between the morning and afternoon overpasses in high-AOD conditions minus that in low-AOD conditions, is different over land and ocean. This applies to cloud droplet effective radius (CDR), cloud fraction (CF) and cloud top pressure (CTP), but not to cloud optical thickness (COT) and cloud liquid water path (CWP). Both COT and CWP increase over land and ocean after the time step, irrespective of the AOD. However, the initial AOD conditions can affect the amplitude of variation of COT and CWP. The effects of initial cloud fraction and meteorological conditions on the change in CF under lowand high-AOD conditions after the 3 h time step over land are also explored. Two cases are considered: (1) when the cloud cover increases and (2) when the cloud cover decreases. For both cases, we find that almost all values of d(CF) are positive, indicating that the variations of CF are larger in high AOD than that in low AOD after the 3 h time step. The results also show that a large increase in cloud fraction occurs when scenes experience large AOD and stronger upward motion of air parcels. Furthermore, the increase rate of cloud cover is larger for high AOD with increasing relative humidity (RH) when RH is larger than 20 %. We also find that a smaller increase in cloud fraction occurs when scenes experience larger AOD and larger initial cloud cover. Overall, the analysis of the diurnal variation of cloud properties provides a better understanding of aerosol-cloud interaction over land and ocean.Peer reviewe

Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.

The B-cell receptor (BCR) signaling pathway has gained significant attention as a therapeutic target in B-cell malignancies. Recently, several drugs that target the BCR signaling pathway, especially the Btk inhibitor ibrutinib, have demonstrated notable therapeutic effects in relapsed/refractory patients, which indicates that pharmacological inhibition of BCR pathway holds promise in B-cell lymphoma treatment. Here we present a novel covalent irreversible Btk inhibitor PLS-123 with more potent anti-proliferative activity compared with ibrutinib in multiple cellular and in vivo models through effective apoptosis induction and dual-action inhibitory mode of Btk activation. The phosphorylation of BCR downstream activating AKT/mTOR and MAPK signal pathways was also more significantly reduced after treatment with PLS-123 than ibrutinib. Gene expression profile analysis further suggested that the different selectivity profile of PLS-123 led to significant downregulation of oncogenic gene PTPN11 expression, which might also offer new opportunities beyond what ibrutinib has achieved. In addition, PLS-123 dose-dependently attenuated BCR- and chemokine-mediated lymphoma cell adhesion and migration. Taken together, Btk inhibitor PLS-123 suggested a new direction to pharmacologically modulate Btk function and develop novel therapeutic drug for B-cell lymphoma treatment